New Zealand agreement secures 1,200 Felix cartridges
Memphasys (ASX: MEM) has signed its first New Zealand commercial agreement for Felix, its sperm preparation technology. The two-year agreement is with Health New Zealand | Te Whatu Ora and will supply Fertility Plus, a government-operated IVF clinic at Auckland’s Greenlane Clinical Centre.
The agreement specifies a minimum purchase volume of 1,200 Felix cartridges over the initial term, beginning with 500 cartridges and one Felix console. Each procedure uses a single-use cartridge, which supports Memphasys’ recurring consumables business model.
Commercial unit pricing is not disclosed.
Marjan Mikel, Chair of the Memphasys Commercialisation Committee
“The commitment to purchase 1,200 cartridges provides a strong foundation in New Zealand, where we intend to operate directly alongside Australia to protect margins and deliver excellent customer support…”
When big ASX news breaks, our subscribers know first
Key terms of the Health NZ agreement
The material terms set out in the announcement are:
- Initial two-year term commencing 1 November 2026
- Further 24-month renewal period available to Health NZ
- Minimum purchase volume of 1,200 cartridges over the initial term, subject to rollover provisions for any unmet volume
- Initial delivery of 500 cartridges and one console scheduled within 30 days of execution, followed by scheduled quarterly deliveries
- Additional orders may be placed
The agreement is non-exclusive and subject to its contractual termination provisions.
Direct Australia-New Zealand strategy and wider footprint
Home-market direct-to-clinic approach
Memphasys is focused on establishing a leading direct-to-clinic presence across its home markets of Australia and New Zealand. The stated aims are maximising market penetration, protecting margins and strengthening customer relationships.
Memphasys’ Monash IVF national supply agreement already gives the company a contracted presence across a 22-clinic network representing roughly 21% of the Australian IVF market.
The strategy is designed to capture greater commercial value while delivering superior clinical and technical support. It complements the company’s expanding international go-direct commercial/distribution approach and other strategic partnerships.
International momentum
The New Zealand agreement follows commercial agreements across:
- Europe
- Australia
- Asia
- the Middle East
Memphasys remains focused on growing its IVF clinic installed base and converting customer adoption into repeat cartridge purchases.
The latest European distribution agreement with INVIDO LAB adds about A$674,000 in minimum contracted purchases across the Czech Republic, Slovakia and Kazakhstan.
The company’s forward-looking statements note that planned deployment, orders, recognised revenue and cash receipts are distinct measures.
What happens next for Memphasys
The announcement points to the following sequence:
- Term start: the initial two-year term was due to commence on 1 November 2026, ahead of the 9 November 2026 announcement, and has now commenced.
- Initial delivery: 500 cartridges and one Felix console, scheduled within 30 days of execution, supplying Fertility Plus under Health NZ.
- Ongoing deliveries: scheduled quarterly deliveries following the initial delivery.
- Renewal: a further 24-month renewal period available to Health NZ after the initial term.
Don’t Miss the Next Healthcare Breakout
Join 20,000+ investors getting FREE breaking ASX news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to receive healthcare and other non-resource alerts the moment market-moving announcements land, so you stay ahead of the market.